Hemab Therapeutics (COAG) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $32.52, +8.62% vs the prior close of $29.94.
- Volume 478.30K shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
COAG jumps 8.6% to $32.52. Closed at $32.52, +8.62% vs the prior close of $29.94. Day range $30.20–$33.50, opened at $30.20.
COAG daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — COAG jumps 8.6% to $32.52
- Closed at $32.52, +8.62% vs the prior close of $29.94. Day range $30.20–$33.50, opened at $30.20.
- Volume was 478.30K shares, 1.1x its 50-day average of 453.28K.
- Price is -21.5% vs its 50-day average ($41.42).
- 52-week range $23.00–$55.42; today's close sits at 29% of that range, 41.3% below the 52-week high.
Oct 14, 2026 — COAG rises 0.5% to $29.94
- Closed at $29.94, +0.47% vs the prior close of $29.80. Day range $29.01–$30.42, opened at $29.75.
- Volume was 224.90K shares, 0.5x its 50-day average of 458.47K — lighter than usual.
- Price is -28.3% vs its 50-day average ($41.78).
- 52-week range $23.00–$55.42; today's close sits at 21% of that range, 46.0% below the 52-week high.
Oct 13, 2026 — COAG dips 1.9% to $29.80
- Closed at $29.80, -1.94% vs the prior close of $30.39. Day range $29.11–$31.05, opened at $30.59.
- Volume was 442.00K shares, 1.0x its 50-day average of 463.62K.
- Price is -29.2% vs its 50-day average ($42.11).
- 52-week range $23.00–$55.42; today's close sits at 21% of that range, 46.2% below the 52-week high.
Oct 12, 2026 — COAG slides 3.9% to $30.39
- Closed at $30.39, -3.89% vs the prior close of $31.62. Day range $30.20–$32.15, opened at $31.68.
- Volume was 235.00K shares, 0.5x its 50-day average of 467.87K — lighter than usual.
- Price is -28.3% vs its 50-day average ($42.41).
- 52-week range $23.00–$55.42; today's close sits at 23% of that range, 45.2% below the 52-week high.
Oct 9, 2026 — COAG rises 2.4% to $31.62, 3 up days in a row
- Closed at $31.62, +2.36% vs the prior close of $30.89. Day range $29.98–$33.93, opened at $30.65.
- Volume was 619.10K shares, 1.3x its 50-day average of 471.91K.
- Price is -26.0% vs its 50-day average ($42.75).
- 52-week range $23.00–$55.42; today's close sits at 27% of that range, 42.9% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — COAG jumps 7.6% to $30.89
- Closed at $30.89, +7.63% vs the prior close of $28.70. Day range $27.39–$31.31, opened at $28.60.
- Volume was 616.40K shares, 1.3x its 50-day average of 469.94K.
- Price is -28.3% vs its 50-day average ($43.07).
- 52-week range $23.00–$55.42; today's close sits at 24% of that range, 44.3% below the 52-week high.
Oct 7, 2026 — COAG rises 1.2% to $28.70
- Closed at $28.70, +1.16% vs the prior close of $28.37. Day range $27.38–$28.98, opened at $28.25.
- Volume was 377.20K shares, 0.8x its 50-day average of 471.00K.
- Price is -33.8% vs its 50-day average ($43.35).
- 52-week range $23.00–$55.42; today's close sits at 18% of that range, 48.2% below the 52-week high.
Oct 6, 2026 — COAG slides 7.3% to $28.37, a 3-month low
- Closed at $28.37, -7.26% vs the prior close of $30.59. Day range $28.01–$30.89, opened at $30.81.
- Volume was 436.80K shares, 0.9x its 50-day average of 469.99K.
- Price is -35.1% vs its 50-day average ($43.72).
- 52-week range $23.00–$55.42; today's close sits at 17% of that range, 48.8% below the 52-week high.
Oct 5, 2026 — COAG dips 1.7% to $30.59, a 3-month low
- Closed at $30.59, -1.67% vs the prior close of $31.11. Day range $29.76–$31.11, opened at $31.11.
- Volume was 294.50K shares, 0.6x its 50-day average of 479.70K.
- Price is -30.7% vs its 50-day average ($44.16).
- 52-week range $23.00–$55.42; today's close sits at 23% of that range, 44.8% below the 52-week high.
Oct 2, 2026 — COAG ends flat (+0.2%) to $31.11
- Closed at $31.11, +0.16% vs the prior close of $31.06. Day range $30.06–$31.49, opened at $31.49.
- Volume was 354.10K shares, 0.7x its 50-day average of 483.34K.
- Price is -30.1% vs its 50-day average ($44.49).
- 52-week range $23.00–$55.42; today's close sits at 25% of that range, 43.9% below the 52-week high.
COAG latest news & SEC filings
Every SEC filing by or about COAG in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 25, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$24.15M (prior year -$12.21M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.80 (prior year -$12.91) (loss narrowed vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade COAG
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 21, 2026. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.28% (largest 8.6%). That is a volatile stock.
- Liquidity: about 626.15K shares (≈$20.36M) trade per day on average.
- 52-week position: $32.52 vs a range of $23.00–$55.42 (29% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Capital Management, L.P. Ra bought 61,523 shares on Jun 16, 2026.
- Latest filings: 8-K Sep 24, 2026; 10-Q Aug 11, 2026; 8-K Aug 11, 2026.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
COAG market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 30.20 | 33.50 | 30.20 | 32.52 | 478.30K |
| Oct 14, 2026 | 29.75 | 30.42 | 29.01 | 29.94 | 224.90K |
| Oct 13, 2026 | 30.59 | 31.05 | 29.11 | 29.80 | 442.00K |
| Oct 12, 2026 | 31.68 | 32.15 | 30.20 | 30.39 | 235.00K |
| Oct 9, 2026 | 30.65 | 33.93 | 29.98 | 31.62 | 619.10K |
| Oct 8, 2026 | 28.60 | 31.31 | 27.39 | 30.89 | 616.40K |
| Oct 7, 2026 | 28.25 | 28.98 | 27.38 | 28.70 | 377.20K |
| Oct 6, 2026 | 30.81 | 30.89 | 28.01 | 28.37 | 436.80K |
| Oct 5, 2026 | 31.11 | 31.11 | 29.76 | 30.59 | 294.50K |
| Oct 2, 2026 | 31.49 | 31.49 | 30.06 | 31.11 | 354.10K |
| Oct 1, 2026 | 30.82 | 31.35 | 29.63 | 31.06 | 437.80K |
| Sep 30, 2026 | 32.92 | 33.27 | 30.80 | 30.84 | 865.20K |
| Sep 29, 2026 | 32.99 | 33.95 | 31.80 | 32.60 | 452.00K |
| Sep 28, 2026 | 34.39 | 34.41 | 32.60 | 33.12 | 348.50K |
| Sep 25, 2026 | 35.70 | 36.10 | 34.74 | 34.74 | 266.50K |
| Sep 24, 2026 | 36.89 | 37.64 | 34.01 | 35.72 | 401.30K |
| Sep 23, 2026 | 38.38 | 38.98 | 34.99 | 36.73 | 417.10K |
| Sep 22, 2026 | 38.53 | 39.81 | 37.42 | 38.25 | 550.10K |
| Sep 21, 2026 | 41.20 | 43.21 | 37.54 | 37.97 | 556.80K |
| Sep 18, 2026 | 41.67 | 42.31 | 40.85 | 41.19 | 4.15M |
About Hemab Therapeutics
Hemab Therapeutics (COAG) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 2114044.
COAG board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Linda Bain | Director | Apr 30, 2026 |
| John Maraganore | Director | May 4, 2026 |
| Capital Nexus Fund Ii, L.P. Ra | Director | May 6, 2026 |
| Capital Nexus Fund Iv, L.P. Ra | Director | May 6, 2026 |
| Benny Sorensen | See Remarks | Apr 30, 2026 |
| Laura Tadvalkar | Director | Apr 30, 2026 |
| Akshay Vaishnaw | Director | Apr 30, 2026 |
| Keli Walbert | Director | Sep 25, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Mads Nikolaj Behrndt-Eriksen | See Remarks | May 4, 2026 |
| Catherine Madigan | Chief Medical Officer | May 4, 2026 |
| Ananthram Sreenivasa Murthy | Chief Operating Officer | Apr 30, 2026 |
| Benny Sorensen | See Remarks | Apr 30, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 16, 2026 | Capital Management, L.P. Ra | Buy | 61,523 | $24.98 |
| Jun 16, 2026 | Peter Kolchinsky | Buy | 61,523 | $24.98 |
| Jun 16, 2026 | Capital Healthcare Fund Lp Ra | Buy | 61,523 | $24.98 |
| Jun 16, 2026 | Rajeev M. Shah | Buy | 61,523 | $24.98 |
| Jun 15, 2026 | Capital Management, L.P. Ra | Buy | 6,146 | $24.89 |
| Jun 15, 2026 | Peter Kolchinsky | Buy | 6,146 | $24.89 |
| Jun 15, 2026 | Capital Healthcare Fund Lp Ra | Buy | 6,146 | $24.89 |
| Jun 15, 2026 | Rajeev M. Shah | Buy | 6,146 | $24.89 |
| May 20, 2026 | Capital Management, L.P. Ra | Buy | 996 | $24.94 |
| May 20, 2026 | Capital Healthcare Fund Lp Ra | Buy | 996 | $24.94 |
| May 20, 2026 | Rajeev M. Shah | Buy | 996 | $24.94 |
| May 20, 2026 | Peter Kolchinsky | Buy | 996 | $24.94 |
| May 19, 2026 | Capital Management, L.P. Ra | Buy | 3,802 | $24.97 |
| May 19, 2026 | Capital Healthcare Fund Lp Ra | Buy | 3,802 | $24.97 |
| May 19, 2026 | Rajeev M. Shah | Buy | 3,802 | $24.97 |
COAG financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $467.78M, total liabilities $13.51M, cash $237.37M (as of Jun 30, 2026).
COAG earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $51.74 |
| May 21, 2026 | 8-K Item 2.02 (results) | $26.30 |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on COAG
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.